Alzheimer’s Disease and the Bradykinin-Forming Cascade
Author Information
Author(s): Kaplan Allen P., Ghebrehiwet Berhane, Joseph Kusumam
Primary Institution: The Medical University of South Carolina
Hypothesis
Can inhibiting the bradykinin-forming cascade improve the progression of Alzheimer's disease?
Conclusion
The study suggests that targeting the bradykinin-forming pathway may offer a new therapeutic approach for Alzheimer's disease.
Supporting Evidence
- Aggregated Aβ activates the plasma bradykinin-forming pathway.
- Activation of the pathway is proportional to the extent of memory loss in patients.
- Bradykinin levels are elevated in patients with severe Alzheimer's disease.
Takeaway
This study found that a protein related to Alzheimer's can activate a process in the blood that might make the disease worse, and blocking this process could help treat the disease.
Methodology
The study reviewed existing data and conducted in vitro experiments to assess the activation of the bradykinin-forming cascade by aggregated Aβ protein.
Potential Biases
Potential conflicts of interest due to author affiliations with pharmaceutical companies.
Limitations
The study primarily relies on existing literature and in vitro findings, which may not fully translate to in vivo conditions.
Participant Demographics
The study references findings from patients with Alzheimer's disease but does not provide specific demographic details.
Statistical Information
P-Value
0.029
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website